Staff View: Angiotensin receptor neprilysin inhibitor as a novel antihypertensive drug: Evidence from Asia and around the globe

Angiotensin receptor neprilysin inhibitor as a novel antihypertensive drug: Evidence from Asia and around the globe

Hypertension is a worldwide epidemic that continues to grow, with a subset of patients responding poorly to current treatment available. This is especially relevant in Asia, which constitutes 61% of the global population. Hypertension in Asia is a unique entity that is often salt-sensitive, nocturna...

Full description

Saved in:

Bibliographic Details
Main Authors:	Lin, Donna S-H, Wang, Tzung-Dau, Buranakitjaroen, Peera, Chen, Chen-Huan, Cheng, Hao-Min, Chia, Yook Chin, Sukonthasarn, Apichard, Tay, Jam Chin, Teo, Boon Wee, Turana, Yuda, Wang, Ji-Guang, Kario, Kazuomi, Network, HOPE Asia
Format:	Article
Published:	Wiley 2021
Subjects:	R Medicine RC Internal medicine
Online Access:	http://eprints.um.edu.my/34533/
Tags:	Add Tag No Tags, Be the first to tag this record!

id	my.um.eprints.34533
record_format	eprints
spelling	my.um.eprints.345332022-05-30T07:27:49Z http://eprints.um.edu.my/34533/ Angiotensin receptor neprilysin inhibitor as a novel antihypertensive drug: Evidence from Asia and around the globe Lin, Donna S-H Wang, Tzung-Dau Buranakitjaroen, Peera Chen, Chen-Huan Cheng, Hao-Min Chia, Yook Chin Sukonthasarn, Apichard Tay, Jam Chin Teo, Boon Wee Turana, Yuda Wang, Ji-Guang Kario, Kazuomi Network, HOPE Asia R Medicine RC Internal medicine Hypertension is a worldwide epidemic that continues to grow, with a subset of patients responding poorly to current treatment available. This is especially relevant in Asia, which constitutes 61% of the global population. Hypertension in Asia is a unique entity that is often salt-sensitive, nocturnal, and systolic predominant. Sacubitril/valsartan is a first-in-class angiotensin receptor neprilysin inhibitor that was first used in heart failure with reduced ejection fraction. Sacubitril inhibits neprilysin, a metallopeptidase that degrades natriuretic peptides (NPs). NPs exert sympatholytic, diuretic, natriuretic, vasodilatory, and insulin-sensitizing effects mostly via cyclic guanosine monophosphate (cGMP)-mediated pathways. As an antihypertensive agent, sacubitril/valsartan has outperformed angiotensin II receptor type 1 blockers (ARBs), with additional reductions of office systolic blood pressures ranging between 5 and 7 mmHg, in multiple studies in Asia and around the globe. The drug was well tolerated even in the elderly or those with chronic kidney disease. Its mechanisms of actions are particularly attractive for treatment of hypertension in Asia. Sacubitril/valsartan offers a novel, dual class, single-molecule property that may be considered as first-line antihypertensive therapy. Further investigations are needed to validate its safety for long-term use and to explore other potentials such as in the management of insulin resistance and obesity, which often coexist with hypertension in Asia. Wiley 2021-03 Article PeerReviewed Lin, Donna S-H and Wang, Tzung-Dau and Buranakitjaroen, Peera and Chen, Chen-Huan and Cheng, Hao-Min and Chia, Yook Chin and Sukonthasarn, Apichard and Tay, Jam Chin and Teo, Boon Wee and Turana, Yuda and Wang, Ji-Guang and Kario, Kazuomi and Network, HOPE Asia (2021) Angiotensin receptor neprilysin inhibitor as a novel antihypertensive drug: Evidence from Asia and around the globe. The Journal of Clinical Hypertension, 23 (3, SI). pp. 556-567. ISSN 1524-6175, DOI https://doi.org/10.1111/jch.14120 <https://doi.org/10.1111/jch.14120>. 10.1111/jch.14120
institution	Universiti Malaya
building	UM Library
collection	Institutional Repository
continent	Asia
country	Malaysia
content_provider	Universiti Malaya
content_source	UM Research Repository
url_provider	http://eprints.um.edu.my/
topic	R Medicine RC Internal medicine
spellingShingle	R Medicine RC Internal medicine Lin, Donna S-H Wang, Tzung-Dau Buranakitjaroen, Peera Chen, Chen-Huan Cheng, Hao-Min Chia, Yook Chin Sukonthasarn, Apichard Tay, Jam Chin Teo, Boon Wee Turana, Yuda Wang, Ji-Guang Kario, Kazuomi Network, HOPE Asia Angiotensin receptor neprilysin inhibitor as a novel antihypertensive drug: Evidence from Asia and around the globe
description	Hypertension is a worldwide epidemic that continues to grow, with a subset of patients responding poorly to current treatment available. This is especially relevant in Asia, which constitutes 61% of the global population. Hypertension in Asia is a unique entity that is often salt-sensitive, nocturnal, and systolic predominant. Sacubitril/valsartan is a first-in-class angiotensin receptor neprilysin inhibitor that was first used in heart failure with reduced ejection fraction. Sacubitril inhibits neprilysin, a metallopeptidase that degrades natriuretic peptides (NPs). NPs exert sympatholytic, diuretic, natriuretic, vasodilatory, and insulin-sensitizing effects mostly via cyclic guanosine monophosphate (cGMP)-mediated pathways. As an antihypertensive agent, sacubitril/valsartan has outperformed angiotensin II receptor type 1 blockers (ARBs), with additional reductions of office systolic blood pressures ranging between 5 and 7 mmHg, in multiple studies in Asia and around the globe. The drug was well tolerated even in the elderly or those with chronic kidney disease. Its mechanisms of actions are particularly attractive for treatment of hypertension in Asia. Sacubitril/valsartan offers a novel, dual class, single-molecule property that may be considered as first-line antihypertensive therapy. Further investigations are needed to validate its safety for long-term use and to explore other potentials such as in the management of insulin resistance and obesity, which often coexist with hypertension in Asia.
format	Article
author	Lin, Donna S-H Wang, Tzung-Dau Buranakitjaroen, Peera Chen, Chen-Huan Cheng, Hao-Min Chia, Yook Chin Sukonthasarn, Apichard Tay, Jam Chin Teo, Boon Wee Turana, Yuda Wang, Ji-Guang Kario, Kazuomi Network, HOPE Asia
author_facet	Lin, Donna S-H Wang, Tzung-Dau Buranakitjaroen, Peera Chen, Chen-Huan Cheng, Hao-Min Chia, Yook Chin Sukonthasarn, Apichard Tay, Jam Chin Teo, Boon Wee Turana, Yuda Wang, Ji-Guang Kario, Kazuomi Network, HOPE Asia
author_sort	Lin, Donna S-H
title	Angiotensin receptor neprilysin inhibitor as a novel antihypertensive drug: Evidence from Asia and around the globe
title_short	Angiotensin receptor neprilysin inhibitor as a novel antihypertensive drug: Evidence from Asia and around the globe
title_full	Angiotensin receptor neprilysin inhibitor as a novel antihypertensive drug: Evidence from Asia and around the globe
title_fullStr	Angiotensin receptor neprilysin inhibitor as a novel antihypertensive drug: Evidence from Asia and around the globe
title_full_unstemmed	Angiotensin receptor neprilysin inhibitor as a novel antihypertensive drug: Evidence from Asia and around the globe
title_sort	angiotensin receptor neprilysin inhibitor as a novel antihypertensive drug: evidence from asia and around the globe
publisher	Wiley
publishDate	2021
url	http://eprints.um.edu.my/34533/
_version_	1735409612175179776
score	13.211869

Angiotensin receptor neprilysin inhibitor as a novel antihypertensive drug: Evidence from Asia and around the globe

Similar Items